Biohaven Ltd
BHVN
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contact
c/o Biohaven Pharmaceuticals, Inc
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
256
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,557.40 | 290.20 | -3.70% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,314.86 | 2,231.07 | -5.50% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,849.29 | 2,000.52 | -8.76% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,942.88 | 1,837.70 | -5.44% |
| NZX 50 Index | 11,826.87 | 398.41 | -3.26% |
| S&P 500 | 5,074.08 | 322.44 | -5.97% |
| S&P/ASX 200 | 7,383.80 | 284.00 | -3.70% |
| SSE Composite Index | 3,151.63 | 190.38 | -5.70% |